Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. / Teerlink, John R.; Diaz, Rafael; Michael Felker, G.; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalan, Ramon; Crespo-Leiro, Maria G.; Dahlstrom, Ulf; Echeverria, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Li, Jing; Lund, Mayanna; Macdonald, Peter; Mareev, Viacheslav; Momomura, Shin'ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Varin, Claire; Honarpour, Narimon; Abbasi, Siddique A.; Malik, Fady I.; Kurtz, Christopher E.

In: New England Journal of Medicine, Vol. 384, No. 2, 2021, p. 105-116.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Teerlink, JR, Diaz, R, Michael Felker, G, McMurray, JJV, Metra, M, Solomon, SD, Adams, KF, Anand, I, Arias-Mendoza, A, Biering-Sorensen, T, Bohm, M, Bonderman, D, Cleland, JGF, Corbalan, R, Crespo-Leiro, MG, Dahlstrom, U, Echeverria, LE, Fang, JC, Filippatos, G, Fonseca, C, Goncalvesova, E, Goudev, AR, Howlett, JG, Lanfear, DE, Li, J, Lund, M, Macdonald, P, Mareev, V, Momomura, S, O'Meara, E, Parkhomenko, A, Ponikowski, P, Ramires, FJA, Serpytis, P, Sliwa, K, Spinar, J, Suter, TM, Tomcsanyi, J, Vandekerckhove, H, Vinereanu, D, Voors, AA, Yilmaz, MB, Zannad, F, Sharpsten, L, Legg, JC, Varin, C, Honarpour, N, Abbasi, SA, Malik, FI & Kurtz, CE 2021, 'Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure', New England Journal of Medicine, vol. 384, no. 2, pp. 105-116. https://doi.org/10.1056/NEJMoa2025797

APA

Teerlink, J. R., Diaz, R., Michael Felker, G., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sorensen, T., Bohm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlstrom, U., Echeverria, L. E., Fang, J. C., Filippatos, G., ... Kurtz, C. E. (2021). Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine, 384(2), 105-116. https://doi.org/10.1056/NEJMoa2025797

Vancouver

Teerlink JR, Diaz R, Michael Felker G, McMurray JJV, Metra M, Solomon SD et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. New England Journal of Medicine. 2021;384(2):105-116. https://doi.org/10.1056/NEJMoa2025797

Author

Teerlink, John R. ; Diaz, Rafael ; Michael Felker, G. ; McMurray, John J.V. ; Metra, Marco ; Solomon, Scott D. ; Adams, Kirkwood F. ; Anand, Inder ; Arias-Mendoza, Alexandra ; Biering-Sorensen, Tor ; Bohm, Michael ; Bonderman, Diana ; Cleland, John G.F. ; Corbalan, Ramon ; Crespo-Leiro, Maria G. ; Dahlstrom, Ulf ; Echeverria, Luis E. ; Fang, James C. ; Filippatos, Gerasimos ; Fonseca, Candida ; Goncalvesova, Eva ; Goudev, Assen R. ; Howlett, Jonathan G. ; Lanfear, David E. ; Li, Jing ; Lund, Mayanna ; Macdonald, Peter ; Mareev, Viacheslav ; Momomura, Shin'ichi ; O'Meara, Eileen ; Parkhomenko, Alexander ; Ponikowski, Piotr ; Ramires, Felix J.A. ; Serpytis, Pranas ; Sliwa, Karen ; Spinar, Jindrich ; Suter, Thomas M. ; Tomcsanyi, Janos ; Vandekerckhove, Hans ; Vinereanu, Dragos ; Voors, Adriaan A. ; Yilmaz, Mehmet B. ; Zannad, Faiez ; Sharpsten, Lucie ; Legg, Jason C. ; Varin, Claire ; Honarpour, Narimon ; Abbasi, Siddique A. ; Malik, Fady I. ; Kurtz, Christopher E. / Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. In: New England Journal of Medicine. 2021 ; Vol. 384, No. 2. pp. 105-116.

Bibtex

@article{b348b9d4a72d4023b9574cd7531f6491,
title = "Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure",
abstract = "BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.).",
author = "Teerlink, {John R.} and Rafael Diaz and {Michael Felker}, G. and McMurray, {John J.V.} and Marco Metra and Solomon, {Scott D.} and Adams, {Kirkwood F.} and Inder Anand and Alexandra Arias-Mendoza and Tor Biering-Sorensen and Michael Bohm and Diana Bonderman and Cleland, {John G.F.} and Ramon Corbalan and Crespo-Leiro, {Maria G.} and Ulf Dahlstrom and Echeverria, {Luis E.} and Fang, {James C.} and Gerasimos Filippatos and Candida Fonseca and Eva Goncalvesova and Goudev, {Assen R.} and Howlett, {Jonathan G.} and Lanfear, {David E.} and Jing Li and Mayanna Lund and Peter Macdonald and Viacheslav Mareev and Shin'ichi Momomura and Eileen O'Meara and Alexander Parkhomenko and Piotr Ponikowski and Ramires, {Felix J.A.} and Pranas Serpytis and Karen Sliwa and Jindrich Spinar and Suter, {Thomas M.} and Janos Tomcsanyi and Hans Vandekerckhove and Dragos Vinereanu and Voors, {Adriaan A.} and Yilmaz, {Mehmet B.} and Faiez Zannad and Lucie Sharpsten and Legg, {Jason C.} and Claire Varin and Narimon Honarpour and Abbasi, {Siddique A.} and Malik, {Fady I.} and Kurtz, {Christopher E.}",
note = "Publisher Copyright: Copyright {\textcopyright} 2020 Massachusetts Medical Society.",
year = "2021",
doi = "10.1056/NEJMoa2025797",
language = "English",
volume = "384",
pages = "105--116",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "2",

}

RIS

TY - JOUR

T1 - Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

AU - Teerlink, John R.

AU - Diaz, Rafael

AU - Michael Felker, G.

AU - McMurray, John J.V.

AU - Metra, Marco

AU - Solomon, Scott D.

AU - Adams, Kirkwood F.

AU - Anand, Inder

AU - Arias-Mendoza, Alexandra

AU - Biering-Sorensen, Tor

AU - Bohm, Michael

AU - Bonderman, Diana

AU - Cleland, John G.F.

AU - Corbalan, Ramon

AU - Crespo-Leiro, Maria G.

AU - Dahlstrom, Ulf

AU - Echeverria, Luis E.

AU - Fang, James C.

AU - Filippatos, Gerasimos

AU - Fonseca, Candida

AU - Goncalvesova, Eva

AU - Goudev, Assen R.

AU - Howlett, Jonathan G.

AU - Lanfear, David E.

AU - Li, Jing

AU - Lund, Mayanna

AU - Macdonald, Peter

AU - Mareev, Viacheslav

AU - Momomura, Shin'ichi

AU - O'Meara, Eileen

AU - Parkhomenko, Alexander

AU - Ponikowski, Piotr

AU - Ramires, Felix J.A.

AU - Serpytis, Pranas

AU - Sliwa, Karen

AU - Spinar, Jindrich

AU - Suter, Thomas M.

AU - Tomcsanyi, Janos

AU - Vandekerckhove, Hans

AU - Vinereanu, Dragos

AU - Voors, Adriaan A.

AU - Yilmaz, Mehmet B.

AU - Zannad, Faiez

AU - Sharpsten, Lucie

AU - Legg, Jason C.

AU - Varin, Claire

AU - Honarpour, Narimon

AU - Abbasi, Siddique A.

AU - Malik, Fady I.

AU - Kurtz, Christopher E.

N1 - Publisher Copyright: Copyright © 2020 Massachusetts Medical Society.

PY - 2021

Y1 - 2021

N2 - BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.).

AB - BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.).

UR - http://www.scopus.com/inward/record.url?scp=85099772364&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa2025797

DO - 10.1056/NEJMoa2025797

M3 - Journal article

C2 - 33185990

AN - SCOPUS:85099772364

VL - 384

SP - 105

EP - 116

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -

ID: 279429387